Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial
Jeff P. Sharman(Willamette Valley Cancer Institute and Research Center), Miklós Egyed(Somogy Megyei Kaposi Mór Oktató Kórház), Wojciech Jurczak(The Maria Sklodowska-Curie National Research Institute of Oncology), Alan P Skarbnik(Hackensack University Medical Center), John M. Pagel, Ian W. Flinn(Sarah Cannon), Manali Kamdar(University of Colorado Denver), Talha Munir(St James's University Hospital), Renata Walewska(Royal Bournemouth Hospital), Gillian Corbett(Tauranga Hospital), Laura Fogliatto(Universidade Federal do Rio Grande do Sul), Yair Herishanu(Tel Aviv Sourasky Medical Center), Versha Banerji(CancerCare Manitoba), Steven Coutré(Stanford University), George Follows(Addenbrooke's Hospital), Patricia Walker(Alfred Health), Karin Karlsson(Skåne University Hospital), Paolo Ghia(IRCCS Ospedale San Raffaele), Ann Janssens(KU Leuven), Florence Cymbalista, Jennifer A. Woyach(The Ohio State University), Gilles Salles(Hospices Civils de Lyon), William G. Wierda(The University of Texas MD Anderson Cancer Center), Raquel Izumi(AstraZeneca (United States)), Veerendra Munugalavadla(AstraZeneca (United States)), Priti Patel(AstraZeneca (United States)), Min Hui Wang(AstraZeneca (United States)), Sofia Wong(AstraZeneca (United States)), John C. Byrd(The Ohio State University)
Cited by 601Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis